With DBV Technologies preparing its Biologics License Application for Viaskin Peanut to be filed in the second half of 2018, H.C. Wainwright analyst Andrew Fein is "eager to see the regulators response." He expects the FDA will be swayed by "several points" in favor of DBVT, including the "very low risk" associated with the Viaskin program due to its "excellent safety and tolerability profile," the treatment appearing to generate a level of efficacy that is sufficient to avoid accidental exposure, and the data suggesting that the longer a patient is on the patch, the greater the level of tolerance developed and the greater the likelihood that patients could achieve the minimal threshold for protection. Fein reiterates a Buy rating on DBV shares with a $50 price target.